Mereo Biopharma Group Stock Price Patterns
| MREO Stock | USD 0.37 0.02 5.13% |
Momentum 31
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0) | EPS Estimate Current Year (0.04) | EPS Estimate Next Year (0.02) | Wall Street Target Price 2.6667 | EPS Estimate Current Quarter (0) |
Using Mereo BioPharma hype-based prediction, you can estimate the value of Mereo BioPharma Group from the perspective of Mereo BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Mereo BioPharma using Mereo BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Mereo using crowd psychology based on the activity and movement of Mereo BioPharma's stock price.
Mereo BioPharma Short Interest
An investor who is long Mereo BioPharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about Mereo BioPharma and may potentially protect profits, hedge Mereo BioPharma with its derivative instruments, or be ready for some potential downside.
200 Day MA 1.8215 | Short Percent 0.1152 | Short Ratio 0.5 | Shares Short Prior Month 9.8 M | 50 Day MA 1.0943 |
Mereo BioPharma Group Hype to Price Pattern
Investor biases related to Mereo BioPharma's public news can be used to forecast risks associated with an investment in Mereo. The trend in average sentiment can be used to explain how an investor holding Mereo can time the market purely based on public headlines and social activities around Mereo BioPharma Group. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Mereo BioPharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Mereo BioPharma.
Mereo BioPharma Implied Volatility | 1.1 |
Mereo BioPharma's implied volatility exposes the market's sentiment of Mereo BioPharma Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mereo BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mereo BioPharma stock will not fluctuate a lot when Mereo BioPharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Mereo BioPharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Mereo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Mereo BioPharma after-hype prediction price | USD 0.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Mereo contract
Based on the Rule 16, the options market is currently suggesting that Mereo BioPharma Group will have an average daily up or down price movement of about 0.0688% per day over the life of the 2026-05-15 option contract. With Mereo BioPharma trading at USD 0.37, that is roughly USD 2.54E-4 . If you think that the market is fully incorporating Mereo BioPharma's daily price movement you should consider acquiring Mereo BioPharma Group options at the current volatility level of 1.1%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Mereo BioPharma Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mereo BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mereo BioPharma After-Hype Price Density Analysis
As far as predicting the price of Mereo BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Mereo BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Mereo BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Mereo BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Mereo BioPharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mereo BioPharma's historical news coverage. Mereo BioPharma's after-hype downside and upside margins for the prediction period are 0.02 and 14.74, respectively. We have considered Mereo BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Mereo BioPharma is out of control at this time. Analysis and calculation of next after-hype price of Mereo BioPharma Group is based on 3 months time horizon.
Mereo BioPharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Mereo BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Mereo BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.23 | 14.37 | 0.00 | 0.03 | 10 Events / Month | 3 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.37 | 0.37 | 0.00 |
|
Mereo BioPharma Hype Timeline
Mereo BioPharma Group is now traded for 0.37. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.03. Mereo is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.23%. %. The volatility of related hype on Mereo BioPharma is about 11053.85%, with the expected price after the next announcement by competition of 0.40. About 79.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.33. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mereo BioPharma Group recorded a loss per share of 0.25. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Mereo BioPharma Basic Forecasting Models to cross-verify your projections.Mereo BioPharma Related Hype Analysis
Having access to credible news sources related to Mereo BioPharma's direct competition is more important than ever and may enhance your ability to predict Mereo BioPharma's future price movements. Getting to know how Mereo BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Mereo BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GOVX | GeoVax Labs | 0.65 | 8 per month | 0.00 | (0.32) | 9.38 | (13.98) | 42.89 | |
| BLRX | BioLineRx | 0.07 | 6 per month | 0.00 | (0.09) | 4.73 | (5.26) | 13.04 | |
| THAR | Tharimmune | (0.15) | 8 per month | 5.59 | 0.07 | 11.15 | (9.64) | 29.73 | |
| AIMD | Ainos Inc | 0.06 | 9 per month | 0.00 | (0.12) | 12.30 | (9.79) | 38.73 | |
| LPCN | Lipocine | 0.02 | 6 per month | 3.17 | 0.27 | 15.95 | (7.33) | 33.09 |
Mereo BioPharma Additional Predictive Modules
Most predictive techniques to examine Mereo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mereo using various technical indicators. When you analyze Mereo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Mereo BioPharma Predictive Indicators
The successful prediction of Mereo BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mereo BioPharma Group, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mereo BioPharma based on analysis of Mereo BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mereo BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mereo BioPharma's related companies.
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Mereo Stock
| 0.79 | DRTS | Alpha Tau Medical | PairCorr |
| 0.78 | GXEA | Galapagos NV | PairCorr |
| 0.71 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.66 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.66 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mereo BioPharma Basic Forecasting Models to cross-verify your projections. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Biotechnology sector continue expanding? Could Mereo diversify its offerings? Factors like these will boost the valuation of Mereo BioPharma. Expected growth trajectory for Mereo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mereo BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Mereo BioPharma Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mereo BioPharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mereo BioPharma's market price to deviate significantly from intrinsic value.
Understanding that Mereo BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mereo BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mereo BioPharma's market price signifies the transaction level at which participants voluntarily complete trades.